Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 583

1.

Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.

Shinoff JJ, O'Brien KL, Thumar B, Shaw JB, Reid R, Hua W, Santosham M, Karron RA.

J Infect Dis. 2008 Oct 1;198(7):1007-15. doi: 10.1086/591460.

PMID:
18702606
3.

Role of complement in neutralization of respiratory syncytial virus.

Yoder SM, Zhu Y, Ikizler MR, Wright PF.

J Med Virol. 2004 Apr;72(4):688-94.

PMID:
14981775
4.

Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.

Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM.

J Clin Microbiol. 1986 Aug;24(2):197-202.

5.

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.

J Virol. 2007 Dec;81(24):13710-22.

6.

The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.

Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, O'Brien KL.

Pediatr Infect Dis J. 2008 Mar;27(3):207-12. doi: 10.1097/INF.0b013e31815ac585.

PMID:
18277934
7.

Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze.

Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, Simões EA.

J Allergy Clin Immunol. 2009 Feb;123(2):398-403. doi: 10.1016/j.jaci.2008.10.043.

PMID:
19101023
8.

Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults.

Falsey AR, Walsh EE, Looney RJ, Kolassa JE, Formica MA, Criddle MC, Hall WJ.

J Med Virol. 1999 Oct;59(2):221-6.

PMID:
10459160
9.
11.

Immunopathology of RSV infection: prospects for developing vaccines without this complication.

van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J.

Rev Med Virol. 2007 Jan-Feb;17(1):5-34. Review.

PMID:
17004293
12.
13.

Prevalence of antibodies against HEp-2 cell antigen in infants and children hospitalized with respiratory syncytial virus infection.

Forster J, Maier O, Löbbert J, Kaufmehl K, Streckert HJ, Werchau H.

Infection. 1996 Nov-Dec;24(6):407-11.

PMID:
9007586
14.

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL.

J Infect Dis. 2005 Apr 1;191(7):1093-104.

PMID:
15747245
15.

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.

Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA.

J Virol. 2004 Oct;78(20):11198-207.

16.

Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.

Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S.

Virology. 2008 Aug 15;378(1):79-85. doi: 10.1016/j.virol.2008.04.016.

19.
20.

Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection.

Brandenburg AH, Groen J, van Steensel-Moll HA, Claas EC, Rothbarth PH, Neijens HJ, Osterhaus AD.

J Med Virol. 1997 May;52(1):97-104.

PMID:
9131465
Items per page

Supplemental Content

Support Center